CD274 and gastric cancer: Two phase Ib studies (KEYNOTE 12 and KEYNOTE 28) have evaluated the role of pembrolizumab in PD-L1 expressing gastric cancer and esophageal cancer (SCC and adenocarcinoma), respectively [29, 30].